We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Cogent Biosciences Inc | NASDAQ:COGT | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.52 | -6.74% | 7.20 | 4.77 | 8.20 | 7.81 | 7.41 | 7.73 | 652,864 | 05:00:03 |
From Nov 2023 to May 2024
Poster DetailsThe posters will be available on the ‘Posters and Publications’ page of Cogent’s website when they are presented.
Presentation ID: PO3-26-02Title: Identification of a novel, brain penetrant, EGFR sparing, ErbB2 inhibitor with activity against oncogenic ErbB2 mutationsSession: Poster Session 3Date: Thursday, December 7, 2023Time: 12:00 PM - 2:00 PM CT (1:00 PM – 3:00 PM ET)
Presentation ID: PO3-26-01Title: Preclinical in vitro and in vivo characterization of a novel, wild-type-sparing, PI3Kα H1047R mutant-selective inhibitorSession: Poster Session 3Date: Thursday, December 7, 2023Time: 12:00 PM - 2:00 PM CT (1:00 PM – 3:00 PM ET)
About Cogent Biosciences, Inc. Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Ka (genes/pathways). Cogent Biosciences is based in Waltham, MA and Boulder, CO. Visit our website for more information at www.cogentbio.com. Follow Cogent Biosciences on social media: Twitter and LinkedIn. Information that may be important to investors will be routinely posted on our website and Twitter.
Contact:Christi WaarichSenior Director, Investor Relationschristi.waarich@cogentbio.com617-830-1653
1 Year Cogent Biosciences Chart |
1 Month Cogent Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
